Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort
| Autor: | Salvatore Petta, Antonio Craxì, Giuseppe Malizia, Gaetano Bertino, Giuseppe Cabibbo, Salvatore Battaglia, G. Scifo, Irene Cacciola, Maurizio Russello, Giovanni Squadrito, F. Cartabellotta, Giovanni Raimondo, F. Benanti, Tullio Prestileo, A. Montineri, Vincenza Calvaruso, Calogero Cammà, Salvatore Madonia, Maria Antonietta Di Rosolini, A. Digiacomo, Marco Enea, Marco Distefano, Anna Licata, Vito Di Marco |
|---|---|
| Přispěvatelé: | Calvaruso V., Petta S., Cacciola I., Cabibbo G., Cartabellotta F., Distefano M., Scifo G., Di Rosolini M.A., Russello M., Prestileo T., Madonia S., Malizia G., Montineri A., Digiacomo A., Licata A., Benanti F., Bertino G., Enea M., Battaglia S., Squadrito G., Raimondo G., Cammà Calogero., Craxi A., Di Marco V. |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty Cirrhosis Hepatitis C virus Chronic Hepatitis Competing risks Survival Hepacivirus medicine.disease_cause Chronic liver disease competing risk Antiviral Agents Gastroenterology survival chronic hepatiti Virology Diabetes mellitus Internal medicine medicine Humans chronic hepatitis cirrhosis competing risks survival Aged competing risks Hepatology business.industry cirrhosis Hazard ratio Albumin Original Articles Hepatitis C Chronic Middle Aged medicine.disease Hepatitis C digestive system diseases Infectious Diseases Cardiovascular Diseases Cohort Original Article Female chronic hepatitis business Kidney disease cirrhosi |
| Zdroj: | Journal of Viral Hepatitis |
| Popis: | Real-world evidence on the course of Hepatitis C Virus (HCV) chronic liver disease after Sustained Virologic Response (SVR) obtained with direct-acting antiviral drugs (DAAs) are still limited, and the effects on mortality remain unclear. We evaluated the post-treatment survival of 4307 patients in the RESIST-HCV cohort (mean age 66.3±11.6years, 56.9% males, 24.7% chronic hepatitis, 66.9% Child-Pugh A cirrhosis and 8.4% Child-Pugh B cirrhosis) treated with DAAs between March 2015 and December 2016 and followed for a median of 73weeks (range 16–152). Proportional cause-specific hazard regression for competing risks was used to evaluate the survival and to assess the predictors of liver and cardiovascular death. Overall, 94.7% of patients achieved SVR while 5.3% were HCV RNA-positive at last follow-up. Sixty-three patients (1.4%) died during the observation period. SVR was associated with a decreased risk of liver mortality (hazard ratio,HR0.09, beta −2.37, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|